Skip to main content
. Author manuscript; available in PMC: 2019 Jan 15.
Published in final edited form as: Cancer Res. 2017 Nov 27;78(2):451–462. doi: 10.1158/0008-5472.CAN-17-1803

Figure 4. Tumor suppressor activity of TAp63 and ΔNp63 in cancer progression.

Figure 4

a, Normalized enrichment score (NES) of upregulated and downregulated cancer progression signatures in TAp63−/− and ΔNp63−/− signatures. b, Activity score of TAp63KIRC, TAp63KIRP and TAp63LGG in corresponding cancer patients at high and low grade/stages. c, Kaplan-Meier survival of kidney clear cell (KIRC), kidney papillary (KIRP) and low grade glioma (LGG) patients with respect to the corresponding TAp63 signature activity. d, Activity score of ΔNp63BLCA, ΔNp63KIRC, ΔNp63KIRP and ΔNp63LGG in corresponding cancer patients at high and low grade/stages. e, Kaplan-Meier survival of bladder cancer (BLCA), KIRC, KIRP and LGG patients with respect to the corresponding ΔNp63 signature activity. f, Kaplan-Meier survival within Stage IV KIRC, Stage III/IV KIRP and Grade (G) 3 LGG with respect to TAp63KIRC, TAp63KIRP and TAp63LGG activities. g, Kaplan-Meier survival within Stage IV KIRC, and G2 and G3 LGG patients with respect to ΔNp63KIRC and ΔNp63LGG activities, respectively. Number of cases in each survival group is listed between parenthesis where indicated.